Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study
A considerable proportion of Danish EBC patients meet high-risk criteria similar to CDK4/6 inhibitor trial populations and experience inferior outcomes despite standard therapy of antihormone treatment +/- chemotherapy. Our real-world data underscore the need for more effective and less toxic adjuvant therapies such as CDK4/6 inhibitors.
Authors
- Maj‐Britt Jensen (ORCID: https://orcid.org/0000-0001-5348-3040)
- Ida Christine Jacobsen (ORCID: https://orcid.org/0000-0003-0653-4364)
- Tobias Berg (ORCID: https://orcid.org/0000-0003-2006-6616)
- Ann Søegaard Knop
Institutions
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Danish Breast Cancer Cooperative Group (DK)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2025-11-12
- DOI
- https://doi.org/10.2340/1651-226x.2025.44003
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00